INTRODUCTION {#s1}
============

Bladder cancer (BC) is the fourth most common cancer in men in the US with an incidence of 20.3 per 100000 in both sexes \[[@R1]\]. In the EU, the age-standardised incidence rate is as high as 16.3 \[[@R2]\]. Muscle invasive BC (MIBC) accounts for 20-25% of newly diagnosed cases of BC whereas the remaining present as non muscle invasive BC (NMIBC); over 50% of NMIBCs recur, while 15-20% advance towards a muscle-invasive form \[[@R3]\].

High-grade (previously G3) stage T1 (T1G3) BC is considered the most challenging form of NMIBC due to its high propensity to recur and progress to muscle invasive disease. Long-term progression and death rates as high as 53% and 34%, respectively, have been reported \[[@R4]\]. Most important, T1G3 has an unpredictable behaviour as one third of patients never recur or progress, one third requires deferred cystectomy and another third eventually dies of this disease independently on given treatment \[[@R5]\]. Therefore, the identification of factors predicting disease behaviour represents a major clinical issue.

To date, prediction of recurrence and progression on NMIBC including T1G3 BC relies on two scoring systems \[[@R6]\], namely the European Organization for Research and Treatment of Cancer (EORTC) and the Club Urologico Espanol de Tratamiento Oncologico (Spanish Urological Oncology Group, CUETO) scoring systems. Both systems however suffer the bias of being based on patients with different tumor stage and grade and having received different treatment. Accordingly, current European Association of Urology (EAU) guidelines on NMIBC \[[@R6]\] acknowledge that "research is needed to determine the role of molecular markers in improving the predictive accuracy of currently existing risk tables".

In the last 20 years, great efforts have been made to identify molecular markers that could prognosticate T1G3 BC behavior or predict its response to "standard treatment", *i.e*. complete transurethral resection of the bladder tumor (TURBT) and intravesical instillation of Bacillus Calmette Guerin (BCG). Markers such as p53, pRb, p21, and survivin, have proved their predictive value in studies including a homogeneous patient population on standardized treatment, and therefore seem to be ready for clinical use \[[@R7]\]. Moreover, novel molecules are emerging not only as potential prognostic/predictive markers but also as potential therapeutic targets \[[@R8]\].

Human epidermal growth factor receptor 2 (HER-2) is a 185-kDa transmembrane tyrosine kinase receptor and a member of the epidermal growth factor receptor family located on chromosome 17q21. It is involved in oncogenesis via activation of intracellular pathways leading to proliferation, angiogenesis, cell survival, and metastatic potential \[[@R9]--[@R12]\].

While HER-2 overexpression is a well established marker of poor prognosis and poor response to therapies in both breast cancer \[[@R13]\], and advanced gastro-esophageal cancer \[[@R10]\], its role in BC remains controversial. HER-2 overexpression rate has been reported to vary from \<10 to \>80 %, and data regarding its prognostic relevance are conflicting \[[@R14]--[@R16]\]. Most studies focused on MIBC, whereas little attention has been dedicated to NMIBC, particularly T1G3, which is the most risky one.

Therefore, in the present study we tested, in a homogeneous population of T1G3 BCs, the role of HER-2 expression in predicting recurrence and progression in patients treated and not treated with BCG immunotherapy, in order to uncover its role as prognostic and predictive marker.

RESULTS {#s2}
=======

A total of 67 patients fulfilled all of the study inclusion and exclusion criteria; their mean age was 71.7±9.89 years. As expected, patients who underwent BCG treatment were younger than those who did not (67.9±10.56 vs. 75.3±7.84 years, respectively; p=0.002). Patients' characteristics and treatment they received are summarized in Table [1](#T1){ref-type="table"}.

###### Patients' demographic and pathologic characteristics

  Variable                       Overall67 pts   BCG34 pts   No BCG33 pts   *p*-value
  ------------------------------ --------------- ----------- -------------- -----------
  MaleFemale                     598             304         294            1.000
  PrimarySecondary               598             304         294            1.000
  SingleMultiple                 4918            2410        258            0.784
  Size \<3cmSize \>3cm           3136            1717        1419           0.628
  HER-2 negativeHER-2 positive   3829            1816        2013           0.624

At median follow-up of 75.7 months (range 9-133), recurrent NMIBCs were found in 35 patients; of them, 8 experienced subsequent disease progression (7 local and 1 associated to liver metastases). Conversely, 9 patients experienced direct disease progression (8 local and 1 associated to multiple pulmonary metastases). Thirteen patients underwent radical cystectomy, 4 because of recurrent T1G3 disease and 9 because of local disease progression. The 4 patients who underwent cystectomy for recurrent T1G3 disease were excluded from progression-free survival (PFS) evaluation, as we felt inappropriate to compare those who had a "radical" treatment with those who stayed on "conservative" treatment Fourteen patients eventually died, 10 from their BC and 4 from other causes. Therefore, the overall disease- survival (DFS), PFS and cancer specific survival (CSS) rates were 35.8%, 73.0% and 85.1%, respectively.

The estimated study power was 94% for the overall patients population, 83% for patients treated and 70% for patients not-treated with BCG. Kaplan-Meier estimators and log-rank tests showed that traditional prognostic factors (Table [2](#T2){ref-type="table"}) failed to predict DFS and PFS both in patients treated and not-treated with BCG; conversely, HER-2 status (Table [2](#T2){ref-type="table"}) was found to be a significant predictor of DFS in the overall patients population (p=0.0013) as well as in patients treated and not-treated with BCG (p=0.0140 and 0.0125, respectively); it also was a significant predictor of PFS in the overall patients population (p=0.0322) but not in patients treated and not-treated with BCG (p=0.1290 and 0.1696, respectively).

###### Univariate survival analysis according to Kaplan-Meier method and the Logrank test

  Variable                              Disease-Free Survival   Progression-Free Survival                                      
  ------------------------------------- ----------------------- --------------------------- ------------ ------------ -------- --------
  Male *vs*. Female                     0.3400                  0.3430                      0.5647       0.3355       0.1887   0.9311
  Primary *vs*. Recurrent               0.1926                  0.5363                      0.1614       0.6409       0.0519   0.2591
  Single *vs*. Multiple                 0.4756                  0.7956                      0.2035       0.6412       0.8857   0.3905
  Size \<3cm *vs*. \>3cm                0.3926                  0.2524                      0.7226       0.7417       0.2783   0.4515
  HER-2 negative *vs*. HER-2 positive   **0.0013**              **0.0140**                  **0.0125**   **0.0322**   0.1290   0.1696

The two patients populations (treated and not-treated with BCG) had, by chance, similar prognostic factors (Table [1](#T1){ref-type="table"}); this finding allowed to evaluate the effect of BCG treatment on disease outcome. The disease-free rate was 47.1% (16/34) in patients who received (mean 85.29mo) and 24.2% (8/33) in patients who did not received BCG treatment (mean 65.33mo); the difference in DFS was statistical significant (p=0.0231) in the overall population (Figure [1A](#F1){ref-type="fig"}) and was close to but did not reach statistical significance when patients were stratified according to HER-2 status (Figures [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). The progression-free rate was 69.7% (10/33) in patients who received and 76.7% (7/30) in patients who did not received BCG treatment; the difference in PFS was not statistically significant (p=0.6901) in the overall population (Figure [1B](#F1){ref-type="fig"}) nor when patients were stratified according to HER-2 status (Figures [2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}).

![Kaplan-Meier curves of disease-free **(A)** and progression-free survival **(B)** in patients treated (1) or not (0) with BCG.](oncotarget-08-25433-g001){#F1}

![Kaplan-Meier curves of disease-free **(A and B)** and progression-free survival **(C and D)** according to HER-2 status (Panel A and C = HER-2 negative; Panel B and D = HER-2 positive).](oncotarget-08-25433-g002){#F2}

Multivariate Cox proportional-hazards regression analysis (Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}) pointed out that both HER-2 overexpression and BCG treatment were significant predictors (p= 0.001 and 0.012, respectively) of DFS, whereas HER-2 overexpression was the only significant predictor of PFS (p=0.041).

###### Multivariate Cox proportional-hazards regression analysis

  Variable               Disease-Free Survival   Progression-Free Survival                                           
  ---------------------- ----------------------- --------------------------- ----------- -------- ------------------ -----------
  BCG treatment          0.4493                  0.2412 to 0.8369            **0.012**   1.0484   0.3947 to 2.7844   0.924
  HER-2 overexpression   2.7968                  1.5117 to 5.1747            **0.001**   2.8161   1.0410 to 7.6184   **0.041**

HR: Hazard ratio

![Survival curves according to multivariate Cox proportional-hazards regression analysis\
**(A and C)**: disease-free and progression free survival according to HER-2 status; **(B and D)**: disease-free and progression free survival according to BCG treatment.](oncotarget-08-25433-g003){#F3}

The Kendal test showed a positive correlation between HER-2 overexpression and tumor recurrence (tau-b=0.4013; p=0.001) and progression (tau-b=0.2648; p=0.0353). Sensitivity, specificity, and predictive values (positive and negative) are reported in Table [4](#T4){ref-type="table"} while Figure [4](#F4){ref-type="fig"} displays ROC curves for DFS and PFS. The predictive accuracy (c-index) for DFS of a model including only BCG was 58.8% and raised to 66.8% by adding HER-2 expression; similarly, the c-index for PFS was 51.1% when including only BCG, and 62.6% when adding HER-2 expression.

###### Sensitivity, specificity, positive (PPV) and negative predictive values of HER-2 overexpression in predicting DFS and PFS

  HER-2 overexpression   Disease-Free Survival   Progression-Free Survival
  ---------------------- ----------------------- ---------------------------
  Sensitivity            58% (95% CI 43%-73%)    65% (95% CI 42%-87%)
  Specificity            83% (95% CI 68%-98%)    65% (95% CI 51%-79%)
  PPV                    86% (95% CI 74%-99%)    41% (95% CI 22%-59%)
  NPV                    53% (95% CI 37%-69%)    83% (95% CI 71%-96%)

![Roc Curve of disease-free **(A)** and progression-free survival **(B)** according to HER-2 status (0=negative; 1=positive).](oncotarget-08-25433-g004){#F4}

DISCUSSION {#s3}
==========

The present study was designed to test the prognostic role of HER-2 expression in patients with T1G3 BC and its ability to predict response of such population to BCG treatment. As a matter of fact, it ended up to provided relevant information not only on the role of this marker but also on the role of BCG in the management of T1G3 BC.

In the overall population, HER-2 overexpression was found to be a significant predictor of DFS and PFS performing significantly better than "traditional" prognostic factors (sex, tumor size/number/recurrence), on which the currently available (EORTC and CUETO) risk calculators are based. In the subanalysis of the two populations, however, HER-2 overexpression was found to be a significant predictor of DFS but not of PFS, as the difference in progression-free rate (56.25 *vs*. 82.35% in patients treated and 63.6 *vs*. 84.2% in those not treated with BCG) failed to reach statistical significance probably due to the low number of episodes.

HER-2 overexpression in BC has first been reported by Zhau et al. in 1990 \[[@R17]\]. While it seems to be a reliable prognostic factor in MIBC \[[@R11]\], its role in NMIBC remains controversial. Recently, Chen et al. reported that a subset of high-grade NMIBCs contained HER-2 amplification and were associated with markedly aggressive behavior \[[@R18]\]. Conversely, Olsson et al. reported no significant association between HER-2 status and prognosis in 285 patients with primary T1 BC \[[@R19]\]. Finally, Ding et al. \[[@R20]\] demonstrated that HER-2 overexpression was a significant predictor of progression, especially in patients with intermediate- and high- risk EORTC scores. All these studies, however, are severely biased by heterogeneity of tumor stage and grade, as well as of given treatment. Bongiovanni et al. \[[@R21]\] recently tested the prognostic role of HER-2 expression in 83 patients with T1G3 BC and found that this marker was not a significant predictor or tumor recurrence or progression. Again, it is not clear whether or not these patients received adjuvant BCG treatment after TURBT; moreover, none of them received restaging TUR at any stage. The strength of our study is having tested the role of HER-2 expression in a homogeneous population of patients with T1G3 BC having undergone a well-defined treatment (TUR alone vs. TUR+ BCG induction and 1 year maintenance) and having had a negative restaging TUR. This careful patients selection should guarantee for reliability of obtained results.

As mentioned above, our study provided relevant information also on the role of BCG in the management of T1G3 BC as the two patients populations (treated and not-treated with BCG) were comparable not only for stage and grade (T1G3) but also for "traditional" and "novel" prognostic factors such as HER-2 status. To our knowledge, there is only one previous study \[[@R22]\] comparing the outcome of TUR+BCG with TUR alone in a homogeneous population of T1G3 BCs whereby the two groups of patients had similar clinical and pathological features. BCG treatment provided significantly longer DFS, PFS and even CSS than TUR alone and was far more important than "traditional" clinical and pathological prognostic factors in predicting disease outcome. Our study confirmed that BCG treatment was far more important than "traditional" prognostic factors in predicting disease outcome. It also showed that BCG treatment provided a DFS but not a PFS advantage, that better DFS was achieved in both HER-2 negative and HER-2 positive patients, and that after all HER-2 status was far more important than BCG in predicting both DFS and PFS.

There is increasing evidence in literature that tumor biological characteristics, as expressed by molecular markers, may impact on disease outcome much more than the available "conservative" treatment (TUR+BCG). Shariat et al. \[[@R23]\] demonstrated that the higher the number of altered markers, the greater the risk of progression of NMIBCs of different stages and grades. We previously demonstrated, in a homogeneous population of T1G3 BCs treated with BCG (induction and 1 year maintenance), that altered Retinoblastoma protein (pRB) expression was a significant predictor of disease recurrence and progression \[[@R24]\] but that altered expression of both pRb and p53 was associated with a 50% risk of disease progression, as compared to 0% in patients wild-type or with altered expression of only one of these two markers \[[@R25]\]. To date, assessment of multiple molecular markers having proved their independent value in a homogeneous patients population seems to be the real way forward in the management of this challenging disease \[[@R7], [@R8]\].

Potential limitations of our study include its retrospective nature, but this applies to all studies presently available, and its relatively small sample size, but we believe that a well selected and homogeneous population provides more valuable information than a larger but not homogeneous one. Finally, our study did not provide information on potential benefit of "aggressive" treatment, *i.e*. early radical cystectomy, in patients with T1G3 BC and HER-2 overexpression as this was not our policy in such tumors.

In conclusion, in a homogeneous population of patients with T1G3 BC having undergone "conservative" treatment, HER-2 expression proved to be the most significant predictor of disease-free and progression-free survival, performing significantly better than "traditional" prognostic factors as well as of BCG treatment. Such findings provide grounds for further testing this marker in the setting of T1G3 BC and possibly incorporating it in a panel of markers that could reliably predict the outcome of this challenging disease.

MATERIALS AND METHODS {#s4}
=====================

The study population consisted of 84 patients who underwent complete TURBT from January 2005 to September 2012 and were diagnosed with T1G3 BC by a single uropathologist (FS). Inclusion criteria were: i) bladder muscle clearly identifiable and free of disease; ii) negative restaging TURBT (including random bladder biopsies) within 4 months after the first TURBT; iii) complete follow-up data. Exclusion criteria were: i) presence of concomitant carcinoma in situ; ii) shift from no adjuvant treatment to adjuvant BCG during follow-up, or incomplete BCG treatment; iii) intravesical instillation of a single-dose mytomycin C (MMC) at the end of first TURBT. Patients who did not receive BCG treatment actually refused it; "complete" BCG treatment included induction with one intravesical instillation (Pasteur strain, 75 mg in 50 ml saline) once a week for 6 consecutive weeks, followed by maintenance (one instillation every 3 months for 1 year).

Follow-up consisted of urine cytology and cystoscopy every 3 months for the first two years, every 6 months for the third year, and then yearly. Abdominal computed tomography was performed at initial diagnosis and then every second year to rule out upper tract disease. Tumor recurrence was defined as pathological evidence of disease at bladder biopsy or TURBT, whereas tumor progression was defined as pathological shift to muscle invasive disease at bladder biopsy or TURBT or imaging techniques demonstrating recurrent bladder cancer and distant metastasis likely correlated to it.

The study design was approved by the Internal Review Board.

Immunohistochemistry {#s4_1}
--------------------

Serial sections 4 μm-thick were cut from formalin-fixed paraffin-embedded tissue, deparaffinized in xylene, rehydrated in graded ethanol solutions, washed for 5 minutes with distilled water and mounted on poly-L-lysine-coated glass slides. HER-2 expression was assessed by standard linked streptavidin-biotin horseradish peroxidase (LSAB-HRP) technique using a specific monoclonal antibody against HER2/neu (rabbit monoclonal primary antibody, clone 4B5, PATHWAY) delivered by the Benchmark XT autostainer (Ventana Medical Systems Inc, Tucson, AZ). Positive and negative controls were used. A four-point scale was used: '0′ if there was no membranous staining like normal urothelium \[[@R26]\]; '1+' if there was weak membranous staining in at least 10 % of cells; '2+' if there was moderate membrane staining in at least 10 % of cells; and '3+' if there was strong membranous staining in at least 10 % of cells (Figure [5A-5D](#F5){ref-type="fig"}). Scores of 2+ and 3+ were considered positive \[[@R14], [@R27], [@R28]\]. To confirm immunohistochemical findings, two positive and two negative cases were further tested by silver in situ hybridization (SISH; INFORM Her-2 Dual ISH DNA Probe Cocktail Assay, Ventana Medical Systems, Inc.) analysis; in both positive cases, HER-2 amplification was seen in the form of increased HER-2 gene/chromosome 17 ratio. All cases were independently reviewed by another senior pathologists (PB) unaware of clinical data and the original diagnosis; he also reviewed agreement with the latest WHO Classification of Tumours of the Urinary System and Male Genital Organs \[[@R29]\] and the 2010 TNM staging system \[[@R30]\].

![Immunohistochemical expression of HER-2 scored as 0-absence of staining (A), 1+ (B), 2+ (C) and 3+ (D)](oncotarget-08-25433-g005){#F5}

Statistical analysis {#s4_2}
--------------------

Study power was tested by post-hoc power analysis. Univariate survival analysis was carried out using the Kaplan--Meier method, with differences among groups being tested for significance using the Log-rank test. Multivariate analysis of probable prognostic factors for survival was performed with Cox\'s proportional hazard regression analysis. Differences in rates were tested with the Fisher\'s exact test, whereas differences between continuous variable were tested with the Student\'s t-test.

The correlation between HER-2 expression and tumor recurrence/progression was evaluated by the Kendall test. The diagnostic accuracy of HER-2 expression was assessed by calculating sensitivity, specificity, positive and negative predictive values (PPV, NPV); ROC curves were drawn. The predictive accuracy was evaluated using the Harrell concordance index (c-index) and expressed as percentage.

Statistical analysis was carried out using the STATA SE 14 (StataCorp, College Station, Texas, USA). Significance was set at p\<0.05.
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